Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

1.910 -0.210 (-9.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,426,491
Open 1.880
Bid (Size) 1.910 (1,600)
Ask (Size) 1.920 (1,700)
Prev. Close 2.120
Today's Range 1.580 - 1.950
52wk Range 0.6930 - 46.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are moving in today's session ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill

Performance

YTD
+56.6%
+56.6%
1 Month
+83.7%
+83.7%
3 Month
+29.1%
+29.1%
6 Month
-81.8%
-81.8%
1 Year
-78.2%
-78.2%

More News

Read More
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
bioAffinity Technologies Stock Cools Off After Strong Friday Rally - Here's Why ↗
Via Benzinga
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
These stocks are making the most noise in today's session. ↗
Via Chartmill
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? ↗
Via Benzinga
Topics Intellectual Property

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Common Stock publicly traded?
Yes, bioAffinity Technologies, Inc. - Common Stock is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Common Stock trade on?
bioAffinity Technologies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Common Stock?
The ticker symbol for bioAffinity Technologies, Inc. - Common Stock is BIAF on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Common Stock?
The current price of bioAffinity Technologies, Inc. - Common Stock is 1.910
When was bioAffinity Technologies, Inc. - Common Stock last traded?
The last trade of bioAffinity Technologies, Inc. - Common Stock was at 03/16/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.